secwatch.observer — SEC 8-K summary
======================================

Issuer:     Septerna, Inc. (SEPN)
CIK:        0001984086
Form:       8-K
Filed at:   2024-11-20T23:59:59+00:00
Accession:  0001193125-24-262539
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Septerna reports Q3 2024 net loss of $20.5M; cash runway into H2 2027 after IPO
-------------------------------------------------------------------------------

- Net loss of $20.5M for Q3 2024; R&D expenses $17.8M, G&A $4.9M.
- Cash, equivalents, and marketable securities $137.5M as of Sep 30, 2024; plus $302.6M net IPO proceeds in Oct 2024 extend runway into H2 2027.
- Phase 1 trial of SEP-786 (oral PTH1R agonist for hypoparathyroidism) ongoing; data expected mid-2025.
- SEP-631 (MRGPRX2 NAM for CSU) in IND-enabling studies; TSHR NAM program for Graves' disease progressing.
- Jae Kim, M.D. appointed CMO in September 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1984086/000119312524262539/0001193125-24-262539-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1984086/000119312524262539/d888285d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-262539

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer